Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ublituximab plus umbralisib in chronic lymphocytic leukemia patients already treated with BTK inhibitors was terminated, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2023-07-24